The Latest Cardiac and Vascular News
Largest ever real-world analysis of Cardiac Implantable Electronic Device (CIED) infection treatment presented at the American College of Cardiology’s 71st Annual Scientific Session [1] demonstrates that approximately 4 in 5 patients are not treated according to HRS/EHRA Class I guidelines [2,3] for CIED infection In the absence of guideline-driven care, […]
– ETESIAN Phase 2b study of ION449 (AZD8233) met its primary and secondary endpoints; ION449 was generally well tolerated – ION449 demonstrated potential best-in-class efficacy profile for a self-administered subcutaneous monthly dose regimen – Study findings warrant further clinical development of ION449 for patients with hypercholesterolemia at high cardiovascular risk CARLSBAD, Calif., April 4, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. […]
Health and fitness leaders Jack Seitz and Lara Rosenbaum join CONNEQT’s executive team, bringing a combined 45 years of digital health marketing talent IRVINE, Calif., April 4, 2022 /PRNewswire/ — CardieX Limited (ASX: CDX), a global health technology company focused on cardiovascular disease and vascular health disorders, today announces the addition of notable experts in the health and fitness […]
Clinical Study Confirms Ability to Identify Lung Congestion with Medical-Grade Accuracy TEL AVIV, Israel and WASHINGTON, D.C. – April 4, 2022 – Donisi Health, a MedTech company working to disrupt the readmission cycle of congestive heart failure (CHF) patients, announced results of a clinical study demonstrating the efficacy of its […]
Medtronic adds to its robust clinical program with long-term data demonstrating the continued blood pressure lowering effect of the Symplicity renal denervation procedure Medtronic also completes enrollment in the SPYRAL HTN-ON MED trial DUBLIN and WASHINGTON, April 4, 2022 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced long-term data […]
No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction in METEORIC-HF Healthcare Resource Utilization and Cost Analysis from GALACTIC-HF Demonstrate Treatment with Omecamtiv Mecarbil Led to 19% Cost Reduction Per Patient in Key Subgroup Additional Results from GALACTIC-HF Indicate Treatment with Omecamtiv […]
New Analyses of thousands of patients spanning Phase 2 and pooled Phase 3 data demonstrate that NEXLETOL safely and significantly lowers LDL-C compared to placebo in patients with renal impairment or hypertension ANN ARBOR, Mich., April 03, 2022 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today presented two new analyses from […]
SILVER SPRING, Md., April 04, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), today announced the Company has filed a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for CanGaroo® RM Antibacterial Envelope, its next-generation biomaterial envelope for use with implantable electronic devices (IED). Aziyo Biologics is […]
Guidelines issued jointly by the American Heart Association, American College of Cardiology and Heart Failure Society of America New guidelines recommend the use of SGLT inhibitors for the prevention and treatment of heart failure and highlight the need to improve optimization of medical therapies during hospitalizations THE WOODLANDS, Texas, April 04, […]
– NT-proBNP, a biomarker of cardiac failure and independent predictor of mortality in ATTR-CM patients, was stable or improving throughout the study. At Month 30, median change from baseline in NT-proBNP was -437 pg/mL with 68% of participants observing NT-proBNP levels below their baseline – Serum TTR levels were sustainably […]
